Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

General and administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Ocugen, Inc.

Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. Its product pipeline candidates include OCU400, OCU410, OCU200, and COVAXIN. The firm's modifier gene therapy platform is engaged in addressing retinal diseases, including retinitis pigmentosa, leber congenital amaurosis, and dry age-related macular degeneration. The company was founded by Shankar Musunuri and Uday B. Kompella in 2013 and is headquartered in Malvern, PA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Ocugen reports progress in gene therapy trials amidst financial stability

Ocugen's Q1 2024 performance reflects a mix of financial stability and regulatory milestones.
The company's strengths lie in its promising gene therapy platform and efficient cost management.
Challenges include timeline pressures for upcoming trial updates and ongoing financial constraints.
Opportunities arise from market expansion potential, investor confidence, and strategic partnerships.

Ocugen reports strong Q3 progress with key approvals and financial stability

Ocugen's Q3 2024 earnings call highlighted notable achievements in clinical advancements, regulatory approvals, and financial stability, positioning the company for future growth.
With a focus on advancing key pipeline candidates and managing expenses effectively, Ocugen aims to capitalize on opportunities for expansion and partnership collaborations.
While facing challenges in meeting timelines and ensuring successful trial outcomes, Ocugen remains optimistic about the potential of its innovative therapies to address unmet medical needs.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Ocugen's stock is up more than 5% after the latest clinical trial results showed its Covid-19 vaccine booster shot had positive results. The post OCGN Stock Alert: Why Is Ocugen Gaining Today?

OCGN Stock Alert: Why Is Ocugen Gaining Today?

Shares of Ocugen Inc. OCGN, -1.69% were up 8.1% in premarket trading on Monday, two days after a preprint came out Friday outlining Phase 2 clinical trial results for a COVID-19 booster dose being developed by Bharat Biotech, a privately held biotech based in Hyderabad. A preprint is a type of preliminary medical research that has not been peer-reviewed and is a common way to put out scientific information during the pandemic.

Ocugen's stock gains 8% on promising COVID-19 booster data from partner Bharat Biotech

Ocugen Inc (NASDAQ: OCGN) announced that a booster shot of the COVID-19 vaccine candidate generated over a 10-fold increase in antibody levels across a range of coronavirus variants. Disclosing the Phase 2 data posted by its partner Bharat Biotech for Covaxin, Ocugen said that the studies on its effectiveness against the Omicron variant are ongoing.

Ocugen Reveals Data From Bharat Biotech Partnered Covaxin Booster Dose

MALVERN, Pa., Jan. 08, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutics and vaccines, announced that its partner, Bharat Biotech, posted positive results from a Phase 2 analysis of the vaccine candidate, COVAXIN™ (BBV152), in participants ages 12-64, receiving a booster dose six months following a second dose on the pre-print server, medRxiv. The analysis found that participants receiving a booster dose saw a significant increase in neutralizing titers, an important predictor of vaccine efficacy.

COVAXIN™ (BBV152) Booster Dose Study Demonstrates Robust Immune Responses and Long-Term Safety

Could Ocugen Become the Next Moderna?

MALVERN, Pa., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc . (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to fight COVID-19, today announced that it will be participating in H.C. Wainwright's Bioconnect Conference taking place next week on January 10-13, 2022.

Ocugen, Inc. to Present at Upcoming H.C. Wainwright Bioconnect Conference

Novavax

Pfizer

Investors seem to be seeing a light at the end of the tunnel with the COVID-19 pandemic despite the present darkness.

Why Pfizer, Novavax, and Ocugen Stocks Are Sinking Today

There has been very good news about the COVID vaccine; however, the jab still hasn't been approved where it counts for the biotech.

Why Ocugen Sank Friday After Soaring Thursday

Ocugen (OCGN) gains on Bharat Biotech's positive results from a study in the pediatric population.

Ocugen (OCGN) Up on Bharat Biotech's Data in Pediatric Group

Co-Diagnostics

Sorrento Therapeutics Inc

Even with COVID-19 cases rising, the prospects for these stocks remain uncertain.

Why Co-Diagnostics, Ocugen, and Sorrento Stocks Are Sinking This Week

There was some very good news about its partner's coronavirus vaccine.

Why Ocugen Trounced the Market on Thursday

Energy Focus

Meten Holding Group Ltd.

Check these penny stocks out for your watchlist right now The post These Penny Stocks Are Climbing Right Now, Here's Why appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

These Penny Stocks Are Climbing Right Now, Here's Why

Shares of Ocugen Inc. OCGN, +6.74% surged 6.4% in morning trading Thursday, to bounce off a near 11-month low, after the biopharmaceutical company said its partner, Bharat Biotech, reported positive results from a trial of its COVID-19 vaccine candidate. In a Phase 2/3 trial in India, the company said Covaxin demonstrated in children 2-to-18 years old a "robust" neutralizing antibody response and "favorable" safety profile on the pre-print server.

Ocugen's stock bounces after 'positive' results from COVID-19 vaccine candidate in children as young as 2 years old

MALVERN, Pa., Dec. 30, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Nasdaq: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutics and vaccines, announced today that its partner, Bharat Biotech, posted results from a Phase 2/3 trial conducted in India of candidate vaccine, COVAXIN™ (BBV152), in children, aged 2 – 18 years, demonstrating a robust neutralizing antibody response and favorable safety profile on the pre-print server, medRXiv. Using a two-dose regimen administered 28-days apart, antibody responses in subjects were comparable to adult data from a previous phase 3 study. Those results demonstrated a greater than 93% reduction in severe disease. These pediatric data were the basis of Ocugen's pediatric Emergency Use Authorization (EUA) submission in the United States for children 2-18 on November 5, 2021.

Ocugen Partner, Bharat Biotech, Announces Positive Immunogenicity and Safety Data From COVAXIN™ (BBV152), COVID-19 Candidate Vaccine, in Children 2 – 18 YEARS

OCGN stock has a tough path to entry in the North American market and time is not on its side The post Ocugen Stock Is Essentially Back to Being an Eye Disease Play appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now Man Who Called Black Monday: “Prepare Now.

Ocugen Stock Is Essentially Back to Being an Eye Disease Play

Rivian Automotive

These unproven businesses are full of risk.

2 Overpriced Meme Stocks to Avoid in 2022

Though new variants mean people will continue seeking out booster shots, OCGN stock holders shouldn't expect people to want Ocugen's vaccine. The post A Year After Announcing a Big Partnership, Ocugen Is in a Sorry State appeared first on InvestorPlace.

A Year After Announcing a Big Partnership, Ocugen Is in a Sorry State

BioNTech SE

Decreasing concerns about the omicron variant are leading to declining prices for these vaccine stocks.

Why BioNTech, Novavax, and Ocugen Stocks Are Slipping Today

Ocugen Inc. (NASDAQ:OCGN) shares are trading higher Tuesday as the stock attempts to recover a key support level. The stock looks to have no company specific news to explain the jump in price, but was trending higher on social media sites throughout the day.

Ocugen Shares Move Higher, Try To Recover A Key Technical Level

Keep in mind it works better as a long-term play than a short-term trade. But if you handle possible future volatility, you may want to buy OCGN stock, as it starts to recover from its recent big drop in price.

Ocugen Stock Is Down but Not Out

MALVERN, Pa., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced the Compensation Committee of the Board of Directors of Ocugen approved the grant of stock options to purchase an aggregate of 6,750 shares of its common stock and restricted stock units (RSUs) covering an aggregate of 1,150 shares of common stock to one newly hired team member. The stock options and RSUs were granted as of December 16, 2021, as material inducements to employment in accordance with Nasdaq Listing Rule 5635(c)(4).

Ocugen, Inc. Announces Inducement Grants Under  Nasdaq Listing Rule 5635(c)(4)

OCGN stock has been on a turbulent ride this morning following updates from Ocugen's partner Bharat Biotech. Here's what to know.

OCGN Stock Alert: What Is Going on With Ocugen Today?

SeaChange International

Society Pass

Are these penny stocks on your watchlist right now? The post Best Penny Stocks to Buy Right Now?

Best Penny Stocks to Buy Right Now? 3 to Watch as 2021 Ends

The new week didn't bring an end to heightened volatility.

Vaccine Stocks Are Rising, but This Biotech Is Monday's Big Nasdaq Winner

The stock price of Ocugen Inc (NASDAQ: OCGN) increased by over 12% pre-market today. This is why it happened.

News for Ocugen, Inc. Stock (OCGN)